Novavax, Inc.
NASDAQ:NVAXBiotechnology
-$0.18 today
- Market cap
- $1.31B
- Beta
- 2.41
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.54
Volume 4.24M
Average 4.58M
NVAX Tax Payables
Taxes owed to authorities that have not yet been paid.
Novavax, Inc.NASDAQ: NVAX
Tax Payables · Q1 FY2026 · quarter ended Mar 2026
Tax payables remains negative
Q1 FY2026 tax payables was $0, compared with $0 a year earlier.
Context
- Tax payables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Tax payables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Tax Payables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Tax Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Tax Payables vs competitors
How NVAX compares with its peers on the latest reported figures
- Peers report in different currencies, so tax payables is compared through growth and share of total assets rather than absolute size.
- Tax payables amounts to 0.0% of total assets for NVAX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | €0 EUR | -100.0% | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | €0 EUR | -100.0% | -24.8% | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding NVAX) | — | -100.0% | -24.8% | 0.0% | |
Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.52B | 1.34B | 568.51M | 530.23M | 240.63M |
| Short-term Investments | 0 | 0 | 0 | 392.89M | 494.45M |
| Net Receivables | 454.99M | 82.38M | 297.24M | 108.29M | 106.45M |
| Inventory | 8.87M | 36.68M | 41.7M | 8.75M | 11.55M |
| Other Current Assets | 56.11M | 86.68M | 166.15M | 32.51M | 125.2M |
| Total Current Assets | 2.16B | 1.7B | 1.14B | 1.13B | 978.28M |
| Property, Plant & Equipment (Net) | 228.7M | 400.49M | 490.99M | 300M | 67.7M |
| Goodwill | 131.48M | 126.33M | 127.45M | 107.48M | 113.46M |
| Intangible Assets | 4.77M | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.65M | 1.66M | 0 | 0 | 0 |
| Tax Assets | (1.65M) | (1.66M) | 0 | 0 | 0 |
| Other Non-current Assets | 56.69M | 28.47M | 35.16M | 24M | 17.08M |
| Total Non-current Assets | 421.63M | 555.29M | 653.6M | 431.48M | 198.24M |
| Total Assets | 2.58B | 2.26B | 1.8B | 1.56B | 1.18B |
| Account Payables | 127.05M | 216.52M | 132.61M | 41.58M | 24.58M |
| Short-term Debt | 0 | 324.88M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 1.42B | 370.14M | 241.31M | 675.07M | 140.05M |
| Other Current Liabilities | 74.48M | 982.62M | 917.36M | 279.95M | 236.62M |
| Total Current Liabilities | 2.39B | 2.46B | 1.64B | 1.15B | 459.95M |
| Long-term Debt | 323.46M | 166.47M | 168.02M | 169.68M | 244.21M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 172.53M | 179.41M | 622.21M | 446.82M | 358.94M |
| Other Non-current Liabilities | 42.12M | 55.7M | 33.13M | 359.61M | 239.07M |
| Total Non-current Liabilities | 538.11M | 432.81M | 879.28M | 1.03B | 844.32M |
| Total Liabilities | 2.93B | 2.89B | 2.51B | 2.18B | 1.3B |
| Common Stock | 764K | 868K | 1.41M | 1.62M | 1.65M |
| Retained Earnings | (3.62B) | (4.28B) | (4.82B) | (5.01B) | (4.57B) |
| Accumulated OCI | (1.35M) | (6.38M) | 2.72M | (22.56M) | 2.01M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (351.67M) | (634.08M) | (716.93M) | (623.84M) | (127.75M) |
| Total Debt | 453.99M | 549.78M | 229.08M | 230.42M | 248.81M |
| Net Debt | (1.06B) | (787.1M) | (339.42M) | (299.81M) | 8.18M |
Novavax, Inc.
NASDAQ:NVAX
Intrinsic Alpha fair value
Locked
Current Price
$7.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.